Get the Stockscreener App
178.41
1.04%
-1.88
After Hours:
178.34
-0.07
-0.04%
Overview
News
Price History
Option Chain
Financials
Why MS Down?
Discussions
Forecast
Stock Split
Dividend History
Morgan Stanley stock is traded at $178.41, with a volume of 4.95M.
It is down -1.04% in the last 24 hours and up +5.00% over the past month.
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 80,000 employees as of year-end 2024. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $7.9 trillion in client assets at the end of its most recent fiscal year. After reincorporation as a bank holding company in the wake of the global financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with nearly $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.
See More
Previous Close:
$180.29
Open:
$181.15
24h Volume:
4.95M
Relative Volume:
0.86
Market Cap:
$283.55B
Revenue:
$113.10B
Net Income/Loss:
$16.33B
P/E Ratio:
18.31
EPS:
9.7425
Net Cash Flow:
$10.35B
1W Performance:
+1.08%
1M Performance:
+5.00%
6M Performance:
+35.24%
1Y Performance:
+39.48%
1-Day Range:
$177.75
$181.15
1-Week Range:
$176.06
$181.98
52-Week Range:
$94.33
$181.98
Morgan Stanley Stock (MS) Company Profile
Name
Morgan Stanley
Sector
Industry
Phone
212-761-4000
Address
1585 BROADWAY, NEW YORK, NY
Compare MS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MS
Morgan Stanley
|
178.41 | 286.54B | 113.10B | 16.33B | 10.35B | 9.7425 |
|
GS
Goldman Sachs Group Inc
|
887.96 | 273.24B | 126.58B | 16.67B | 57.26B | 49.23 |
|
SCHW
Charles Schwab Corp
|
96.65 | 172.45B | 27.16B | 8.23B | 20.55B | 4.2633 |
|
HOOD
Robinhood Markets Inc
|
119.50 | 110.94B | 4.23B | 2.19B | -4.36B | 2.4089 |
|
LPLA
Lpl Financial Holdings Inc
|
380.96 | 31.01B | 14.13B | 1.12B | 45.45M | 14.62 |
Morgan Stanley Stock (MS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-03-25 | Initiated | BMO Capital Markets | Outperform |
| Jul-09-25 | Upgrade | Keefe Bruyette | Mkt Perform → Outperform |
| Nov-26-24 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-15-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-11-24 | Downgrade | Goldman | Buy → Neutral |
| Aug-02-24 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-17-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-17-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-17-24 | Downgrade | Keefe Bruyette | Outperform → Mkt Perform |
| Jan-09-24 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Nov-20-23 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Oct-23-23 | Downgrade | Odeon | Buy → Hold |
| Oct-20-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-11-23 | Downgrade | UBS | Buy → Neutral |
| Sep-07-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | Odeon | Hold → Buy |
| Jan-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-10-23 | Upgrade | Odeon | Sell → Hold |
| Jan-04-23 | Downgrade | Wolfe Research | Outperform → Underperform |
| Oct-05-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-06-22 | Downgrade | Odeon | Hold → Sell |
| May-03-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-22 | Downgrade | Odeon | Buy → Hold |
| Dec-03-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-04-21 | Reiterated | Jefferies | Buy |
| Sep-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-28-21 | Downgrade | Berenberg | Buy → Hold |
| Aug-13-21 | Downgrade | Seaport Global Securities | Buy → Neutral |
| Jul-07-21 | Resumed | Keefe Bruyette | Outperform |
| Jun-09-21 | Initiated | Jefferies | Buy |
| Apr-21-21 | Upgrade | Berenberg | Hold → Buy |
| Mar-02-21 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-06-21 | Initiated | Daiwa Securities | Neutral |
| Jan-04-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-13-20 | Resumed | JP Morgan | Overweight |
| Jul-08-20 | Initiated | Seaport Global Securities | Buy |
| Jun-24-20 | Upgrade | DA Davidson | Neutral → Buy |
| Jun-23-20 | Reiterated | UBS | Buy |
| May-21-20 | Upgrade | Odeon | Hold → Buy |
| Apr-14-20 | Upgrade | Societe Generale | Sell → Buy |
| Mar-13-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-04-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-21-20 | Downgrade | DA Davidson | Buy → Neutral |
| Feb-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-21-20 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-13-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jan-09-20 | Initiated | DA Davidson | Buy |
| Jan-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-29-19 | Downgrade | Odeon | Buy → Hold |
| Oct-10-19 | Upgrade | Sandler O'Neill | Hold → Buy |
| Jul-12-19 | Upgrade | Citigroup | Neutral → Buy |
| Apr-18-19 | Downgrade | Citigroup | Buy → Neutral |
View All
Morgan Stanley Stock (MS) Latest News
Morgan Stanley's Katerina Simonetti talks her 2026 market outlook - CNBC
Is the Credit Cycle Overheating? - Morgan Stanley
Form FWP MORGAN STANLEY Filed by: MORGAN STANLEY - StreetInsider
Key facts: Bank of America sees trading demand rise; Morgan Stanley cuts BAC target - TradingView
Morgan Stanley buys commercial space in Lower East Side for $56M - Crain's New York Business
Pfizer Stock (PFE) Gets Cautious 2026 Call from Morgan Stanley — Here’s Why - TipRanks
Morgan Stanley Raises Price Target for Ciena (CIEN) to $195 | CI - GuruFocus
Morgan Stanley Lowers Price Target for DRI to $236 While Maintai - GuruFocus
Legend Biotech (LEGN): Morgan Stanley Lowers Price Target and Ma - GuruFocus
Morgan Stanley Lowers BAC Price Target While Maintaining Overwei - GuruFocus
Does Morgan Stanley’s Upgrade Elevate Old Dominion Freight Line’s Margin Leadership Narrative (ODFL)? - simplywall.st
Morgan Stanley Lowers Price Target for FLUT to $315 | FLUT Stock News - GuruFocus
Veteran Morgan Stanley PM to retire, step off $2bn in funds - Citywire
Fed Cuts Rate: Will This Accelerate Morgan Stanley's IB Fee Growth? - The Globe and Mail
Broadcom's Strong AI Outlook Points to Solid 2026 Setup, Morgan Stanley Says - marketscreener.com
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says - marketscreener.com
Ciena Seeing Strong Demand Aided by 'Leadership' Positions, Morgan Stanley Says - marketscreener.com
REGEuronext DublinGEM-MSIP- Partial Retirement12.12.2025 (MORGAN STANLEY & CO. INTERNATIONAL PLC) [85678] - TradingView
Morgan Stanley Stock (MS) Today: Shares Hover Near Record Levels as Fed Cuts Rates, Analysts Update Targets Ahead of Q4 Earnings - ts2.tech
Morgan Stanley B.V. announces partial cancellation of securities - Investing.com
Morgan Stanley B.V. announces partial cancellation of securities By Investing.com - Investing.com Australia
Morgan Stanley highlights four European gambling stocks to own in 2026 By Investing.com - Investing.com South Africa
Morgan Stanley highlights four European gambling stocks to own in 2026 - Investing.com UK
Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating - marketscreener.com
Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating - marketscreener.com
Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $768 From $767, Maintains Equalweight Rating - marketscreener.com
Morgan Stanley Adjusts Price Target on AbbVie to $269 From $261, Maintains Overweight Rating - marketscreener.com
Morgan Stanley Adjusts Merck & Co. PT to $102 From $100, Maintains Equalweight Rating - marketscreener.com
Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating - marketscreener.com
Morgan Stanley Adjusts Biogen Price Target to $156 From $149, Maintains Equalweight Rating - marketscreener.com
Morgan Stanley Adjusts Bristol-Myers Squibb PT to $37 From $36, Maintains Underweight Rating - marketscreener.com
AbbVie price target raised to $269 from $261 at Morgan Stanley - TipRanks
Morgan Stanley keeps an equal weight rating on KLA Corporation (KLAC) - MSN
Morgan Stanley Analyst Is Bullish On Thermo Fisher Scientific Inc. (TMO) - Yahoo Finance
Morgan Stanley Keeps An Equal Weight Rating On KLA Corporation (KLAC) - Yahoo Finance UK
Got $1,000? 1 Tech Stock to Buy and Hold for Decades. - The Motley Fool
Meta Platforms price target lowered to $750 from $820 at Morgan Stanley - Yahoo Finance
Morgan Stanley price soarsForecast today12-12-2025 - Economies.com
RBC Raises Price Target on Morgan Stanley to $185 From $171, Keeps Sector Perform Rating - marketscreener.com
Coupang stock price target lowered to $31 by Morgan Stanley after data breach - Investing.com
Quantinno Capital Management LP Increases Position in Morgan Stanley $MS - MarketBeat
Planet Labs price target raised to $20 from $4.50 at Morgan Stanley - Investing.com
Morgan Stanley Raises Price Target on Ciena to $195 From $185, Keeps Equalweight Rating - marketscreener.com
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating - marketscreener.com
Morgan Stanley discloses trading activity in Avadel Pharmaceuticals shares - Investing.com
Coupang Inc (CPNG) PT Lowered to $31 at Morgan Stanley - StreetInsider
Synopsys stock price target raised to $550 from $510 at Morgan Stanley - Investing.com
Morgan Stanley Adjusts PT on Johnson & Johnson to $197 From $190, Maintains Equalweight Rating - marketscreener.com
Morgan Stanley discloses trading activity in Avadel Pharmaceuticals By Investing.com - Investing.com Canada
Morgan Stanley discloses trading activity in Avadel Pharmaceuticals shares By Investing.com - Investing.com Canada
Morgan Stanley Adjusts Price Target on Pfizer to $28 From $32, Maintains Equalweight Rating - marketscreener.com
Morgan Stanley Stock (MS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):